Progression on First-Line Therapy in HR+, HER2- MBC: Treatments and Sequencing

601 views
July 24, 2024

In this video, Dr. Joyce O’Shaughnessy discusses the treatment landscape for patients who progress on ET + CDK4/6 inhibitors, including the importance of biomarker testing in this setting.

To access additional videos and download free resources, click here.

VV-OTHR-US-DEL-3129 © 2024 Lilly USA, LLC. All Rights Reserved.

Comments are disabled for this content.